Amedisys (AMED) PT Raised to $125.00 at Cantor Fitzgerald
Amedisys (NASDAQ:AMED) had its price objective hoisted by investment analysts at Cantor Fitzgerald to $125.00 in a note issued to investors on Thursday, The Fly reports. The brokerage presently has a “neutral” rating on the health services provider’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 6.55% from the stock’s current price.
AMED has been the subject of a number of other reports. BidaskClub lowered shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Royal Bank of Canada boosted their target price on shares of Amedisys to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 3rd. Bank of America raised shares of Amedisys from a “neutral” rating to a “buy” rating and boosted their target price for the company from $88.00 to $97.00 in a research note on Tuesday, July 3rd. ValuEngine raised shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 30th. Finally, Canaccord Genuity assumed coverage on shares of Amedisys in a research note on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price for the company. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $87.08.
Amedisys stock opened at $117.32 on Thursday. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.30. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of 53.09, a PEG ratio of 1.89 and a beta of 1.00. Amedisys has a 52-week low of $45.60 and a 52-week high of $127.38.
In other Amedisys news, insider David B. Pearce sold 398 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total transaction of $48,440.58. Following the sale, the insider now directly owns 11,818 shares in the company, valued at approximately $1,438,368.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.60% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. bought a new stake in shares of Amedisys during the 2nd quarter worth about $149,000. SG Americas Securities LLC bought a new stake in shares of Amedisys during the 1st quarter worth about $123,000. Moneta Group Investment Advisors LLC bought a new stake in shares of Amedisys during the 2nd quarter worth about $181,000. Cubist Systematic Strategies LLC raised its position in shares of Amedisys by 1,086.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock worth $203,000 after buying an additional 2,172 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC bought a new stake in shares of Amedisys during the 1st quarter worth about $151,000. Institutional investors own 93.31% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Article: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.